Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:03:09 2023-01-27 pm EST
105.38 USD   -1.39%
01/27Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cancer
MT
01/27FDA Approves KEYTRUDA« (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
BU
01/27Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
109.88(c) 108.52(c) 108.59(c) 106.87(c) 105.38(c) Last
8 998 829 7 424 168 6 167 973 9 672 675 7 784 913 Volume
-0.05% -1.24% +0.06% -1.58% -1.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 59 119 M - -
Net income 2022 14 779 M - -
Net Debt 2022 17 558 M - -
P/E ratio 2022 17,9x
Yield 2022 2,65%
Sales 2023 58 162 M - -
Net income 2023 16 627 M - -
Net Debt 2023 9 650 M - -
P/E ratio 2023 15,8x
Yield 2023 2,82%
Capitalization 267 B 267 B -
EV / Sales 2022 4,82x
EV / Sales 2023 4,76x
Nbr of Employees 67 500
Free-Float 70,8%
More Financials
Company
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (87.8%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of... 
Sector
Pharmaceuticals
Calendar
02/02 | 06:30amEarnings Release
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about MERCK & CO., INC.
01/27Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance..
MT
01/27FDA Approves KEYTRUDA« (pembrolizumab) as Adjuvant Treatment Following Surgical Resecti..
BU
01/27Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA
CI
01/26Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs
MT
01/26Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews..
MT
01/26Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (flu..
BU
01/25Merck & Co.'s Keytruda Combo Prolongs Survival in Late-stage Biliary Tract Cancer Study
MT
01/25Merck to Cease Phase 3 Trial for Treatment of Prostate Cancer Due to Failure in Meeting..
MT
01/25Merck Reports Keytruda Phase 3 Success, Failure
DJ
01/25Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA« (pembrolizumab) Plus Enzalutamid..
BU
01/25Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA« (pembrolizumab) Plus Enzalutamid..
CI
01/25Merck's KEYTRUDA« (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Surv..
BU
01/25Merck’s KEYTRUDA« (pembrolizumab) Plus Chemotherapy Significantly Improved Overall..
CI
01/24Merck & Company Keeps Quarterly Dividend at $0.73 a Share; Payable April 10 to Holders ..
MT
01/24Merck Announces Second-Quarter 2023 Dividend
BU
More news
News in other languages on MERCK & CO., INC.
01/27Merck : la FDA approuve une nouvelle indication du Keytruda
01/27Merck déclare que Keytruda est approuvé par la FDA comme traitement adjuvant du cancer ..
01/27Merck annonce que la Food and Drug Administration (FDA) américaine a approuvé KEYTRUDA
01/26L'unité de santé animale de Merck & Co. reçoit le feu vert de la FDA américaine pour l'..
01/26Merck : a reçu une approbation de la FDA pour BRAVECTO
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
ETFs positioned on MERCK & CO., INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD19.68%-2.37%United_States
ASYMshares ASYMmetric 500 ETF - USD6.28%-0.45%-NC
Invesco Dynamic Pharmaceuticals ETF - USD5.63%0.18%United_States
Nomura NEXT FUNDS International Equity MSCI...5.61%2.67%-World
VanEck Pharmaceutical ETF - USD5.21%-0.87%United_States
More ETFs positioned on MERCK & CO., INC.
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 105,38 $
Average target price 116,38 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Robert M. Davis Chairman & chief executive officer
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Thomas Henry Glocer Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.02%267 180
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-4.87%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
ABBVIE INC.-9.49%258 606